Lumipulse® G pTau 217 Plasma (CE marked (IVDR))
Lumipulse G pTau 217 Plasma is a test for in vitro diagnostic use with the automated LUMIPULSE G System for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human plasma (K2EDTA).
The Lumipulse® G pTau 217 Plasma (CE marked (IVDR))
Receive your quote directly from the manufacturer.
Lumipulse G pTau 217 Plasma is a test for in vitro diagnostic use with the automated LUMIPULSE G System for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human plasma (K2EDTA).
The Lumipulse G pTau 217 Plasma assay is intended to aid Healthcare providers to identify patients with amyloid pathology associated with Alzheimer’s disease.
The test is indicated for patients, aged 50 years and over, presenting with signs and symptoms of cognitive decline in a specialized care setting. The Lumipulse G pTau 217 Plasma assay is to be used as an adjunct to other diagnostic evaluations. This product is for professional use only.
CE marked (IVDR)
Please contact your local Fujirebio representative for the availability of this product in your country.
Expanding access to Alzheimer’s biomarker testing
Early diagnosis can make a meaningful difference for patients and families affected by Alzheimer’s disease and other neurological conditions. In this Fujirebio video, discover how decades of diagnostic innovation, investment in neurodiagnostics, and the work of the Fujirebio Neuro Center of Excellence are helping advance reliable biomarker testing.
Plus, explore Fujirebio’s open partnership model, which is designed to share innovations across platforms and broaden access to advanced assays for laboratories, physicians, and patients worldwide.
How pTau 217 and NfL blood-based biomarkers are reshaping diagnosis in Alzheimer’s and neurodegenerative disease
See why accessible, pathology-informed testing is becoming increasingly important for earlier diagnosis, patient stratification, and more efficient neurological care
